Magazine Article | January 4, 2022

4 Tips For Advancing Your AAV Manufacturing Plans

Source: Life Science Leader

By Tim Kelly

Manufacturing is no simple task for adeno-associated virus (AAV)-based gene therapy and gene editing product development. As the industry advances these genetic medicines, manufacturing is also ramping up, and with it, optimization and efficiencies of scale. Since the industry is still maturing, and manufacturing know-how is often kept proprietary, companies must learn, adapt, and master novel innovations as well as challenges on their own.

access the Magazine Article!

Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Clinical Supply Leader? Subscribe today.

Subscribe to Clinical Supply Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Clinical Supply Leader

Please tell us more about you so that we can customize our newsletters to your specific interests:

What topics interest you? (Check all that apply.)